Yuandong Biotech: Methylene Blue Injection Approved by the U.S. FDA for Drug Registration.

Yuandong Biology announced that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd., has received official approval for the simplified new drug application of Methylene Blue Injection filed with the US FDA. The active ingredient of Methylene Blue Injection is methylene blue, indicated for the treatment of acquired methemoglobinemia in children and adults. According to statistics from the IMS database, the sales of Methylene Blue Injection in the US market in the first three quarters of 2025 amounted to approximately 30.2376 million US dollars.